Vol 94, No 3 (2023)
Research paper
Published online: 2022-05-27

open access

Page views 2590
Article views/downloads 477
Get Citation

Connect on Social Media

Connect on Social Media

Adropin in pregnancy complicated by hyperglycemia and obesity — a preliminary study

Lukasz Adamczak1, Pawel Gutaj1, Ewa Wender-Ozegowska1
Pubmed: 35894495
Ginekol Pol 2023;94(3):229-232.

Abstract

Objectives: According to the data, approximately 33–37% of women of reproductive age are obese. These numbers are reflected in the increasing number of complications in pregnancy, including gestational diabetes.

The study aims to assess the concentrations of adropin in the course of gestational diabetes and their possible relationship with the occurrence of obstetric complications characteristic for it.

Material and methods: The study included 65 obese and overweight pregnant patients (BMI > 27 kg/m2) with glycemic disorders diagnosed during pregnancy. Blood samples we collected during visits: V0 — the first half of pregnancy V1 — 28–32 weeks of gestation, and V2 — 37–39 weeks of gestation. The concentrations of adropin were measured during V1 and V2 by ELISA tests. We analyzed the studied patients' anthropometric, metabolic parameters and obstetrical results.

Results: In the study group, at the visit V1, the mean level of adropin was 525.5 mmol/mL and 588.1 mmol/mL for the V2 visit. The comparison of adropin concentration between visits showed a statistically significant increase (p = 0.02). The concentration of adropin did not differ between obese and morbidly obese patients at V1, but at V2, there was a significant lover adropin level in morbidly obese patients.

Conclusions: In overweight and obese pregnant patients with gestational diabetes, the levels of adropin in serum increased significantly in the last trimester of pregnancy. The increase in concentration was significantly lower in the morbidly obese patients than in the obese group. The study provides the basis for further analyses of the role of adropin in pregnancies complicated by obesity and gestational diabetes.

Article available in PDF format

View PDF Download PDF file

References

  1. Cremona A, O'Gorman C, Cotter A, et al. Effect of exercise modality on markers of insulin sensitivity and blood glucose control in pregnancies complicated with gestational diabetes mellitus: a systematic review. Obes Sci Pract. 2018; 4(5): 455–467.
  2. Koivusalo SB, Rönö K, Klemetti MM, et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care. 2016; 39(1): 24–30.
  3. Diabetology C. 2017 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2017; 6(1): 1–80.
  4. Barrett HL, Dekker Nitert M, D'Emden M, et al. Validation of a triglyceride meter for use in pregnancy. BMC Res Notes. 2014; 7: 679.
  5. Marczuk N, Cecerska-Heryć E, Jesionowska A, et al. Adropin - physiological and pathophysiological role. Postepy Hig Med Dosw (Online). 2016; 70(0): 981–988.
  6. Thapa D, Xie B, Manning JR, et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 2019; 7(8): e14043.
  7. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014; 103(3): 341–363.
  8. Kopelman PG. Obesity as a medical problem. Nature. 2000; 404(6778): 635–643.
  9. Nicolaides KH, Wright D, Syngelaki A, et al. Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound Obstet Gynecol. 2018; 52(1): 44–51.
  10. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013; 41(4): 375–380.
  11. Gao Su, McMillan RP, Zhu Q, et al. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015; 4(4): 310–324.
  12. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012; 97(10): 3783–3791.
  13. Topuz M, Celik A, Aslantas T, et al. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013; 61(8): 1161–1164.
  14. Zang H, Jiang F, Cheng X, et al. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 2018; 65(7): 685–691.
  15. Qiu X, He JR, Zhao MG, et al. Relationship between human cord blood adropin levels and fetal growth. Peptides. 2014; 52: 19–22.